• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next? Product Image

Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?

  • Published: June 2011
  • Region: Global
  • 51 Pages
  • MP Advisors

An estimated 270m to 300m people are infected with Hepatitis C Virus (HCV) worldwide, with about 2.5m to 4.5m pts in the US alone. Recently launched Protease Inhibitors’ Incivek (Vertex/JNJ/Mitsubishi) and Victrelis (Merck/SGP) when added to the old Standard of Care PEGylated- Interferon alpha and Ribavirin have benefited the HCV infected patients - but limitations and unmet need persist.

Major pharmas and research focused companies continue to develop better alternatives. This report is an in-depth analysis of the evolving market. This report looks at the complexities of the disease, the heterogeneity of the patient population and the innovative drugs in the pipeline to fill the gap. More exciting treatment options are on the cards which could bring a major shift in the treatment paradigm for Hepatitis C Viral Infection.

Key Topics Covered Include:
- HCV-Market Overview
- Current and Future Leaders
- Unmet Needs
- Pipeline and Drug Analysis
- NS3- Protease Inhibitors
- NS5B- Polymerase Inhibitors
- NS5A Inhibitors
- Interferon’s
- Interferon Free Combination – An All Oral Option
- Disease Overview and Etiology
- Genotypes 1, 2, 3, 4
- Clinical Trial Design
- Pipeline Failures
- Market Forecasts to 2017

- Executive Summary
- Overview
- Global HCV Market- After the Launch of Protease Inhibitors- After the Launch of Protease Inhibitors
- Unmet Need in HCV
- Leaders in HCV- Past, Present, and Future
- Competitive Landscape - Pipeline
- Key companies Developing Drugs Against HCV
- HCV Pipeline Analysis by Drug Class
- NS3 - Protease Inhibitors
- NS5B - Polymerase Inhibitors
- NS5A Inhibitors
- Interferon’s
- Interferon Free Drug Combination - An All Oral Option
- HCV Vaccines
- Drug Sales Forecast till 2017 - Worldwide
- Background
- Hepatitis C - Disease Cause and Etiology
- HCV Types- Genotype 1, 2, 3, and 4
- Patient Stratification According to Genotype
- HCV Non-responders and Relapsers
- HCV/ HIV Co-infection
- Recurrent HCV Infection Post-transplant
- Virologic Response - RVR, EVR, ETR and SVR
- Clinical Trial Design in HCV and End Points
- Pipeline Failures
- Annexure

Tables:
- Portfolio Of Companies with Best-In-Class HCV Drugs
- Recommended Treatment Duration - Incivek
- Recommended Treatment Duration - Victrelis
- Key Pipeline Products
- Viral Response in Genotype 1 Patients - Protease Inhibitors
- Inhibitors Viral Response In Genotype 1 Patients - Polymerase Inhibitors
- Interim Data from PhIIb Propel Study Of RG7128
- PSI-7977 PhII Data
- Key Pipeline Products - NS5A Inhibitors
- Key Pipeline Products - Interferon’s
- Key Pipeline Products - IFN Free Combinations
- Key Pipeline Products - Vaccine
- Worldwide Market Model
- Cure Rates by Genotype
- Treatment Response
- Pipeline Failures

Figures:
- Worldwide Market Share
- HCV RNA Genome
- NS3 Protease Inhibition
- NS5B Polymerase Inhibition
- NS5A Inhibition
- PEG-IFN-Lambda Antiviral Activity
- IFN Free - Future Treatment Paradigm
- Lifecycle of Hepatitis C Virus
- Stage of Liver Damage
- Different Genotypes in Different Parts of The World
- HCV Infection Testing For Diagnosis
- Algorithm for Treatment - Genotype 1
- Algorithm for Treatment - Genotype 1
- Algorithm for Treatment - Genotype 2 & 3
- HIV & HCV Co-Infection
- Difference Between HIV & HCV Therapy
- Failure To Achieve A Viral Cure

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos